UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

October 11, 2018
Date of report (date of earliest event reported)

Surgery Partners, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-37576**	**47-3620923**
(State or other jurisdictions of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Nos.)

310 Seven Springs Way, Suite 500
Brentwood, Tennessee 37027
(Address of principal executive offices) (Zip Code)

(615) 234-5900
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On October 11, 2018, Surgery Partners, Inc. ("Surgery Partners" or the "Company") announced that it intends to raise $115 million of Incremental Term Loans (the "Incremental Term Loans") to fund an existing pipeline of potential transactions and to replenish proceeds spent in the first half of 2018.

While the Company is still in the process of closing its third quarter ended September 30, 2018, in connection with the Incremental Term Loans, the Company is providing investors with the following preliminary unaudited estimates for the quarter:

- Surgical case volumes are projected to be in the range of 126,000 to 128,000 cases
- Same store revenues are projected to be up in the range of 9% to 11%, with modestly positive case volume growth and strong net revenue per case growth
- Revenues are expected to be in the range of $435 to $445 million

- Adjusted EBITDA is expected to be in the range of $57 to $60 million
- Credit Agreement EBITDA is expected to be in the range of $259 to $262 million

Preliminary Unaudited Selected Financial Data

These preliminary expectations regarding surgical case volumes, same store and total revenues and Adjusted EBITDA and Credit Agreement EBITDA for the quarter ended September 30, 2018 are the responsibility of management and are subject to quarter end and year-end adjustments in connection with the completion of our customary financial closing procedures, including management's review and finalization and to accounting review procedures by our independent registered public accounting firm, which have not yet been performed. Consequently, the results should not be viewed as a substitute for our earnings release and Quarterly Report on Form 10-Q, which are expected to be released no later than November 9, 2018. Actual results may differ materially from our preliminary expectations.

Non-GAAP Financial Measures

Adjusted EBITDA and Credit Agreement EBITDA are financial measures that have not been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and the Company's definition and computation of these non-GAAP financial measures may vary from those used by other companies. These measures have limitations as analytical tools, and should not be considered in isolation or as a substitute or alternative to net income or loss, operating income or loss, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP.

The Company defines the term "Adjusted EBITDA" as income before income taxes adjusted for net income attributable to non-controlling interests, depreciation and amortization, interest expense, net, equity-based compensation expense, contingent acquisition compensation expense, transaction, integration and acquisition costs, reserve adjustments, loss on disposals and de-consolidations, net, gain on litigation settlements and certain other items that we do not believe are representative of our ongoing operations. Credit Agreement Adjusted EBITDA refers to Adjusted EBITDA further adjusted for the impact of hurricanes, synergies and certain other adjustments. The Company is unable to present a quantitative reconciliation of Adjusted EBITDA and Credit Agreement EBITDA to net income/loss for the period presented because management cannot reasonably predict with sufficient reliability all of the necessary components of net income/loss for the periods presented. The Company has excluded the items reflected in the definition of Adjusted EBITDA and Credit Agreement EBITDA above from its projected Adjusted EBITDA and Credit Agreement EBITDA for the period presented and is likely to exclude these

items from Adjusted EBITDA and Credit Agreement EBITDA in the future and may also exclude other similar items, the effect of which is uncertain but may be significant in amount. The determination of the amounts that are excluded from non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts.

Forward-Looking Statements

Certain statements, including statements regarding the Incremental Term Loan, including its anticipated amount and use of proceeds, are forward-looking statements. These statements are subject to risks and uncertainties, including, without limitation, that we may not be able to consummate the Incremental Term Loan transaction on the terms or timeline anticipated, if at all, and, even if the Incremental Term Loan is consummated, we may not be able to consummate acquisitions in the pipeline on commercially reasonable terms, or at all. Management retains broad discretion to use the proceeds of any potential Incremental Term Loan. See also the other factors set forth under "Risk Factors" in the Company's Annual Report on Form 10-K for fiscal year 2017 filed with the Securities and Exchange Commission (the "SEC") and other information we file with the SEC, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2018. You should read the Company's annual and quarterly reports, when available, and any and all other filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements contained in this Current Report speak only as of the date of filing, and the Company undertakes no obligation to update or revise any forward-looking statements for any reason, except as required by law. The business of the Company is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties and should not place considerable reliance on the forward-looking statements contained herein.

Item 7.01 Regulation FD Disclosure

In connection with the Incremental Term Loan described above, the Company intends to make a presentation to prospective lenders. Company is furnishing this presentation as Exhibit 99.1. The information in this Current Report and the exhibit hereto are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	October 2018 Lender Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Surgery Partners, Inc.

By: /s/ Jennifer Baldock
Jennifer Baldock
Senior Vice President, General Counsel

Date: October 11, 2018

Exhibit 99.1

SURGERY PARTNERS

Lender Presentation

October 2018

Legal Disclaimer

Forward-Looking Statements

Statements contained in this presentation, including the question and answer portion of the presentation, other than statements of historical fact, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," or the negative of those terms, and similar expressions and comparable terminology intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the anticipated timing and strength of the opportunities in our pipeline of potential acquisitions, the anticipated timing and terms of the incremental term loan proceeds, as well as the future financial position of Surgery Partners, Inc. and its subsidiaries (the "Company"), including financial targets, business strategy, plans and objectives for future operations and future operating results and cash flows. These statements are subject to risks and uncertainties, including, without limitation: that we may not be able to consummate the incremental term loan transaction on the terms or timeline anticipated, if at all, the impact of natural disasters such as Hurricane Michael or Hurricane Florence whose impact we are continuing to assess, reductions in payments from, or inability to contract with, government healthcare programs managed care organizations and private third-party payors, changes in the regulatory, economic and other conditions of the states where our surgical facilities are located, the timing of the Company's strategic portfolio activity, including acquisitions and dispositions and the conclusion of the Company's review of strategic alternatives for its Optical business, our ability to consummate acquisitions in the pipeline on commercially reasonable terms, or at all, and to realize the anticipated benefits, as well as other factors set forth under "Risk Factors" in the Company's Annual Report on Form 10-K for fiscal year 2017 ("10-K") filed with the Securities and Exchange Commission (the "SEC") and other information we file with the SEC, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2018. You should read the Company's annual and quarterly reports, when available, and any and all other filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements contained in this presentation speak only as of the date of the presentation, and the Company undertakes no obligation to update or revise any forward-looking statements for any reason, except as required by law. The business of the Company is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties and should not place considerable reliance on the forward-looking statements contained in this presentation.

Data and Information Contained in this Presentation

This presentation also contains market research, estimates and forecasts, which is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Certain data in this presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or to update such data after the date of this presentation. Such data involves risks and uncertainties and is subject to change based on various factors. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of such owners.

Non-GAAP Financial Measures

This presentation contains certain non-GAAP financial measures, including EBITDA, Adjusted EBITDA and Credit Agreement EBITDA. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with GAAP in the statements of income, balance sheets or statements of cash flow of the company. We present non-GAAP financial measures when we believe that the additional information is useful and meaningful to investors. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-GAAP financial measures is not intended to be a substitute for, and should not be considered in isolation from, the financial measures reported in accordance with GAAP. For additional information about our non-GAAP financial measures, and a reconciliation of certain non-GAAP financial measures to the comparable GAAP measures, see slide 21 of this presentation, the Company's 10-K, Quarterly Reports on Form 10-Q and other information the Company files with the SEC.

Important Notice Regarding Information Contained in this Presentation

This Lender Presentation (this "Presentation") is intended to facilitate discussions with representatives of certain institutions regarding a potential financing for Surgery Partners, Inc. and its subsidiaries. You should not rely on the information contained in this Presentation and this Presentation does not purport to be all-inclusive or to contain all of the information that a prospective participant may consider material or desirable in making its decision to become a lender. In all cases, prospective participants should conduct their own investigation and analysis of the Company, their assets, financial condition and prospects, and of the data set forth in this Presentation.

Legal Disclaimer

Notice to and Undertaking by Recipients

This Presentation has been prepared solely for informational purposes from information supplied by the Company, and is being furnished by the Company to you in your capacity as a prospective lender (the "Recipient") in considering the proposed Incremental Term Loan described in this Presentation (which may, without limitation, take the form of an increase to the existing Term Loan Facility of Surgery Center Holdings, Inc., a wholly-owned subsidiary of the Company) (the "Incremental Term Loan").

THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OR ANY LOANS OF THE COMPANY OR ANY FINANCIAL INSTRUMENTS RELATED THERETO. THE INFORMATION IN THIS PRESENTATION IS CURRENT ONLY AS OF THE DATE ON ITS COVER. FOR ANY TIME AFTER THE COVER DATE OF THIS PRESENTATION, THE INFORMATION, INCLUDING INFORMATION CONCERNING THE COMPANY'S BUSINESS, FINANCIAL CONDITION, RESULTS OF OPERATIONS AND PROSPECTS, MAY HAVE CHANGED. THE DELIVERY OF THIS PRESENTATION SHALL NOT, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAVE BEEN NO CHANGES IN THE COMPANY'S AFFAIRS AFTER THE DATE OF THIS PRESENTATION. THE COMPANY HAS NOT AUTHORIZED ANY PERSON TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS ABOUT THE COMPANY IN CONNECTION WITH THIS PRESENTATION THAT IS NOT CONTAINED IN THIS PRESENTATION. IF ANY INFORMATION HAS BEEN OR IS GIVEN OR ANY REPRESENTATIONS HAVE BEEN OR ARE MADE TO THE RECIPIENT OUTSIDE OF THIS PRESENTATION, SUCH INFORMATION OR REPRESENTATIONS SHOULD NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ITS AFFILIATES.

I. Information

The Recipient acknowledges and agrees that (i) the Company received certain of the information in this presentation from third party sources is provided to the Recipient for informational purposes only, (ii) Bain Capital Private Equity, LP ("Bain"), the Company and their respective affiliates bear no responsibility (and shall not be liable) for the accuracy or completeness (or lack thereof) of such information or any information contained therein, (iii) no representation or warranty (express or implied) regarding such information is made by Bain, the Company or any of their respective affiliates, (iv) none of Bain, the Company or any of their respective affiliates have made any independent verification as to the accuracy or completeness of such information, (v) Bain, the Company and their respective affiliates shall have no obligation to update or supplement any such information or otherwise provide additional information, (vi) Bain, the Company and their respective affiliates shall not have any liability related to the use of the contents hereof, such information or any related marketing materials by the Recipient or any of its Representatives, (vii) Bain, the Company and their respective affiliates shall not have any liability related to the unauthorized misuse of this Presentation, such information or any related marketing materials by any Recipient or any of its Representatives.

This presentation has been prepared to assist interested parties in making their own evaluation of the Company and the Incremental Term Loan and does not purport to be all-inclusive or to contain all of the information, or a discussion of all or any of the risks, that a prospective participant may consider material or desirable in making its decision to become a lender. The Recipient should take such steps as it deems necessary to assure that it has the information it considers material or desirable in making its decision to provide commitments with respect to the Incremental Term Loans and should perform its own independent investigation and analysis of the Incremental Term Loan and the creditworthiness of the Company. The Recipient represents that it is sophisticated and experienced in extending credit to entities similar to the Company and that it has made its own independent investigations and appraisal of the business, financial condition, prospects, creditworthiness, status and affair of the Company or any other person that it considers necessary.

In addition, this presentation is summary in nature, is subject to change or amendment and is not intended to provide the entire basis for credit or any other evaluation. The information and data contained herein are not a substitute for the Recipient's independent evaluation and analysis and should not be considered as a recommendation that any Recipient enter into the Incremental Term Loan.

II. General

It is understood that, except as otherwise provided herein, the Recipient will be under no legal obligation of any kind whatsoever with respect to the Incremental Term Loan by virtue of this Notice and Undertaking. The Recipient agrees that money damages would not be a sufficient remedy for breach of this Notice and Undertaking, and that in addition to all other remedies available at law or in equity, the Company shall be entitled to equitable relief, including injunction and specific performance, without proof of actual damages.

The loans and commitments under the Incremental Term Loan are not securities under the applicable United States federal securities laws and regulations, and you will not have the protection of such laws and regulations with respect to your purchase and sale of such commitments and loans and the Company will not be required to provide you with any information other than as may be required under the definitive documentation governing the Incremental Term Loan. Additionally, the loans and commitments made under the Incremental Term Loan will not be listed on a securities exchange or any automated dealer quotation system. You may not be able to assign your commitments or loans under the Incremental Term Loan at a particular time or at a price favorable to you. There are no assurances as to the level of liquidity of the market for the commitments or the loans under the Incremental Term Loan.

Transaction Overview

Section 1

Confidential

Transaction Overview

- Surgery Partners, Inc. ("Surgery Partners" or the "Company") is a leading independent operator of short-stay surgical facilities, focused on providing high quality, cost effective solutions for surgical and related ancillary care
  - National network of 124 surgical facilities comprised of 106 ambulatory surgery centers (ASCs) and 18 surgical hospitals across 32 states as of June 30, 2018
  - LTM 6/30/18 Revenue and Credit Agreement EBITDA of $1,628.8 million and $261.2 million, respectively[1]
  - Favorable positioning and industry trends:
    - Strong presence in musculoskeletal cases
    - Aging demographic
    - Recent CMS proposals to increase reimbursement and covered procedures at ASCs
    - Payor alignment due to high quality and lower cost

- Surgery Partners intends to raise $115 million of Incremental Term Loans to fund an existing pipeline of potential transactions and to replenish proceeds spent on acquisitions in H1 2018 on M&A
  - Strong pipeline of near-term capital deployment opportunities, including potential to deploy $113 million of capital towards potential acquisitions (several under LOI), enhanced ownership of existing facilities and de novo activity
  - Current pipeline of potential deployment opportunities, if fully executed, could drive aggregate incremental 6/30/18 Credit Agreement EBITDA of $20.3[1] million, representing a multiple of 5.6x capital deployed to Credit Agreement EBITDA
  - If the full pipeline were executed, the acquisitions, enhanced ownership, and de novo activity could drive deleveraging of total net leverage from 7.8x to 7.6x (pro forma secured net leverage of 4.7x)

(1) For a reconciliation of EBITDA to Credit Agreement EBITDA, please see slide 21 of this presentation.

Sources and Uses and Pro Forma Capitalization

($ in Millions)

(as of 6/30/18)

Pro Forma Capitalization[1]

		Actual		Pro Forma for Incremental Debt	Pro Forma for Capital Deployment
Cash and Cash Equivalents	$	96.1	$	211.1	96.1
Debt					
Revolver ($75 million)		-		-	-
Term Loan		1,280.9		1,280.9	1,280.9
Incremental Term Loan				115.0	115.0
Capital Leases and Facility Level Debt of Wholly Owned Subsidiaries		16.1		16.1	16.1
Total Secured Debt		**1,297.0**		**1,412.0**	**1,412.0**
Senior Unsecured Notes due 2021		400.0		400.0	400.0
Senior Unsecured Notes due 2025		370.0		370.0	370.0
Capital Leases and Facility Level Debt of Non Wholly Owned Subsidiaries[2]		59.8		59.8	59.8
Total Debt		**2,126.8**		**2,241.8**	**2,241.8**
Net Debt		**2,030.7**		**2,030.7**	**2,145.7**
Preferred Equity		342.6		342.6	342.6
Market Capitalization		717.1		717.1	717.1
Total Capitalization	**$**	**3,186.5**	**$**	**3,301.5**	**$ 3,301.5**

		Actual		Pro Forma for Incremental Debt		Pro Forma for Capital Deployment
Surgery Partners	$	261.2	$	261.2	$	261.2
Acquisitions Under LOI						20.3
LTM 6/30/18 Credit Agreement EBITDA	**$**	**261.2**	**$**	**261.2**	**$**	**281.5**
Secured Net Leverage		4.6x		4.6x		4.7x
Total Net Leverage		7.8x		7.8x		7.6x
Equity / Total Capitalization		33.3%		32.1%		32.1%

(1) For a reconciliation of EBITDA to Credit Agreement EBITDA, please see page 21 of this presentation.
(2) Excludes debt of non wholly owned subsidiaries that corresponds to the equity interest share of third parties in such subsidiaries.

Summary of Terms

Borrower	Surgery Center Holdings, Inc.
Facility	$115 million Incremental Term Loan
Guarantors	Same as existing Term Loan
Security	Same as existing Term Loan
Maturity	August 31, 2024 (Same as existing Term Loan)
Pricing	L + 325 (Same as existing Term Loan)
LIBOR Floor	1.0% (Same as existing Term Loan)
New Issue Price	TBD
Amortization	1.0% per year (Same as existing Term Loan)
Voluntary Prepayments	Same as existing Term Loan
Mandatory Prepayments	Same as existing Term Loan
Financial Covenants	None (Same as existing Term Loan)
Negative Covenants	Same as existing Term Loan

Anticipated Transaction Timeline

October 2018						
S	M	T	W	T	F	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31			

Key Event

Date	Title
October 11	Lender call
October 17	Lender commitments due
October 23	Close and fund

Company Update

Section 2

Confidential

Leading Independent Surgical Facility Operator

32 States

106 ASCs

18 Surgical Hospitals

4,000 Affiliated Physicians

600,000+ Annual Patients

$261 million
LTM 6/30/18 Credit Agreement EBITDA[1]



(1) As of June 30, 2018. For a reconciliation of EBITDA to Credit Agreement EBITDA, please see slide 21 of this presentation.

Diversified Mix, Focused on High Value-Add Specialties, Supported by an Aging Population

Surgery Partners Case Mix



- Strength with high acuity patients
- Leading musculoskeletal platform
- Expansive network of surgical capabilities
- Leading trend to lower cost setting

(1) Includes pain management.
(2) Includes cardiology, ENT, general surgery, plastic surgery, and other.

Leading Musculoskeletal Platform is Key to Future Growth

2x
Increase in hip revision procedures projected by 2026

$7 billion
Annual Medicare spend on total joint procedures[1]

100 million
Adults in the U.S. with chronic pain[2]

- ✓ Leading national musculoskeletal surgical facilities operator
- ✓ Reduced Costs for payors and patients over acute care settings
- ✓ Expanded network of total joint, orthopedic and spine capabilities
- ✓ Front-end of industry trend toward moving high acuity cases to lower cost settings

National Surgical Healthcare

OSG

PAIN RELIEF CENTERS

neoSpine

(1) 2014 CMS data: https://innovation.cms.gov/initiatives/cjr.
(2) Institute of Medicine Report from the Committee on Advancing Pain Research, Care, and Education: Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research. The National Academies Press, 2011.

Well Positioned to Capture Incremental Share in a Fragmented Market

Number of ASCs in the U.S.



Source: Definitive Healthcare

Strong, Vertically Integrated Management Team…

Carollee Brinkman
National Group President
22 Years Healthcare Experience
13 Years with Surgery Partners

George Goodwin
American Group President
31 Years Healthcare Experience
20 Years with Surgery Partners

Tony Taparo
Eastern Group President
30 Years Healthcare Experience
22 Years with Surgery Partners

Brandan Lingle
Ancillary Group President
10 Years Healthcare Experience
6 Years with Surgery Partners

Wayne DeVeydt
Chief Executive Officer
25 Years Healthcare Experience
1 Year with Surgery Partners

Jennifer Baldock
EVP & Chief Legal Officer
22 Years Healthcare Experience
9 Years with Surgery Partners

Tom Cowhey
EVP & Chief Financial Officer
17 Years Healthcare Experience
1 Year with Surgery Partners

Angela Justice, PhD
EVP & Chief Human Resources Officer
16 Years Healthcare Experience
1 Year with Surgery Partners

David Kretschmer
EVP & Chief Strategy and Transformation Officer
25 Years Healthcare Experience
1 Year with Surgery Partners

Donna Giles
SVP & Chief Clinical Officer
30 Years Healthcare Experience
5 Years with Surgery Partners

Ben Jacobs
SVP & Chief Development Officer
13 Years Healthcare Experience
4 Years with Surgery Partners

Veteran management team, averaging over 20+ years of experience

… That has Built a Solid Foundation to Capture Growth

Where We Were		Where We Are
Solid, but un-pruned assets	→	Streamlined, surgical facility assets
Great platform, but fragmented	→	Holistic infrastructure
Lack of strategic clarity	→	Focused management and vision

FROM: *A collection of great assets, but under-managed…*

TO: *… A scalable Platform with clear strategic direction and purpose*

Three Primary Initiatives to Drive Profitability and Scale

Pruning the Asset Base

- Data-driven strategic assessment of opportunities and challenges across portfolio
- Divested or shut-down underperforming sites
- Instilled a purpose-driven culture based on transparency, execution, and accountability

Consolidating the Platform

- Initiated enterprise-wide system consolidation
- Consolidated enterprise functions in shared services and commenced realignment of key functions
- Data-driven assessment of value creation related to market development, payor strategy, cost management and revenue cycle management

Investing in the Business

- Strengthened senior management
- Innovative development of long-term partnerships with providers, health systems and payors
- Rebuilt de novo, in-market and M&A pipelines

Recent New Market Acquisitions

Facilities with Strong JV Physician Partners in Attractive Specialties at Reasonable Valuations

Recent Acquisition Activity			
Date Closed	**Location**	**Specialty**	**Capital Deployed**
11/30/2017	Houma, LA	Ortho	~$30m
2/28/2018	Omaha, NE	Ortho, Pain, Spine, Podiatry	~$20m
4/30/2018	Orange County, CA	Pain	~$20m
7/23/2018	Midland, TX	Ophtho, Pain, GI	~$5m
Capital Deployed			**~$75m**

~$75m of Capital deployed in last 12 months

Average Deal multiple at time of acquisition: ~7x

Average Deal multiple expected to improve by 5-10% by end of 2019

Strong Pipeline of Near-term Opportunities

Selected Pipeline Opportunities			
Opportunity	**Status**	**Specialty**	**Target Closing**
A	Under LOI	MSK (spine, pain)	4Q18
B	Under LOI	Ortho, Pain, GYN, Cardio, Spine, Podiatry, Plstcs, Urol	4Q18
C	Won, Negotiating LOI	Ortho, Pain, Spine, Ophtho, GI, ENT, Urology	4Q18/ 1Q19
D	In discussions with existing partners for buy-up	Ortho, Pain, Ophtho, GI, ENT, Urology, OBGYN	4Q18/ 1Q19
E	Management agreements signed; Negotiating LOI	MSK (knees, hips, ankles, spine)	1Q19
F	Applied for CON; De Novo	Ortho, Podiatry, Pain, Spine, Ophtho, Plstcs, Urol	Opens late 2019
Value of Transactions in Pipeline			**~$113m**

Very attractive pipeline of near-term opportunities to deploy ~$113 million of capital

Average Deal multiple of ~5.5x to 6x based on current pipeline

Appendix

Confidential

Historical Financial Summary
As Reported Basis

Net Revenue

($ Million)



Adjusted EBITDA and Adjusted EBITDA Margin

($ Million)

Case Volume



Net Revenue Per Case



(1) For a reconciliation of EBITDA to Adjusted EBITDA and Credit Agreement EBITDA, please see slides 21 of this presentation.

Reconciliation of EBITDA to Adjusted EBITDA and Credit Agreement EBITDA

	2016	2017	LTM 6/30/18
EBITDA	$ 156.7	$ 170.2	$ 172.2
Plus:			
Transaction, Integration & Practice Acquisition Costs [(1)]	11.6	17.0	30.2
Non-cash Stock Compensation Expense	2.0	5.6	8.3
Loss on Debt Extinguishment	11.9	18.2	18.2
Contingent Acquisition Compensation Expense	5.1	7.0	4.2
Gain on Litigation Settlement	(14.1)	(12.5)	(8.7)
Loss on Disposals and Deconsolidations, net	2.4	1.7	3.4
Tax receivable agreement expense (benefit)	3.7	(25.3)	(25.3)
Gain on amendment to TRA		(16.4)	(16.4)
Gain on Acquisition Escrow Release		(1.2)	(1.2)
Reserve adjustments [(2)]			4.8
Adjusted EBITDA	$ 179.3	$ 164.3	$ 189.6
Hurricane Estimated Impact (Q3 2017)			5.0
Reserve Adjustment Impact (Q3 2017)			14.9
Acquisitions and other adjustments [(3)]			51.7
Credit Agreement EBITDA			$ 261.2

(1): This amount includes transaction and integration costs of $26.5 million, $13.1 million and $8.7 million for the last twelve months ended June 30, 2018 and the twelve months ended December 2017 and 2016, respectively, and acquisition costs of $3.7 million, $3.9 million and $2.9 million for the last twelve months ended June 30, 2018 and the twelve months ended December 2017 and 2016, respectively.

(2): This amount represents adjustments to revenue in connection with applying consistent policies across the combined company as a result of the integration of Surgery Partners and NSH.

(3): Represents impact of acquired anesthesia entities, physician practices and surgical facilities as if each acquisition had occurred on July 1, 2017 including cost savings from reductions in corporate overhead, supply chain rationalization, enhanced physician engagement, improved payor contracting and revenue synergies associated with the NSH acquisition. Further, this includes revenue synergies from other business initiatives as defined in the Credit Agreement.

Note: For additional information about our non-GAAP financial measures, and a reconciliation of certain non-GAAP financial measures to the comparable GAAP measures, see the Company's 10-K, Quarterly Reports on Form 10-Q and other information the Company files with the SEC.